Cargando…
Taxol: an important new drug in the management of epithelial ovarian cancer.
Taxol, an antineoplastic agent isolated from the Pacific yew, has been demonstrated in three phase 2 clinical trials to have major activity (30 percent overall response rate) in patients with ovarian cancer refractory to cisplatin. The major toxicities associated with the agent are neutropenia (dose...
Autor principal: | Markman, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Yale Journal of Biology and Medicine
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2589424/ https://www.ncbi.nlm.nih.gov/pubmed/1687343 |
Ejemplares similares
-
Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer
por: Gu, Fei, et al.
Publicado: (2019) -
Platinum-Taxol non-cross resistance in epithelial ovarian cancer.
por: Gore, M. E., et al.
Publicado: (1995) -
New developments in the anti-neoplastic drug management of ovarian cancer
por: Markman, Maurie
Publicado: (2013) -
RASSF1A and the Taxol Response in Ovarian Cancer
por: Kassler, Susannah, et al.
Publicado: (2012) -
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer
por: Markman, Maurie
Publicado: (2011)